Ostarine MK-2866: What the Clinical Evidence Actually Shows

What Is Ostarine MK-2866?

Ostarine is a non-steroidal, orally active SARM originally synthesized to treat muscle-wasting conditions such as cancer cachexia and age-related sarcopenia. It binds the androgen receptor with high selectivity and triggers anabolic signaling in muscle and bone without the full androgenic activity seen with testosterone or anabolic steroids. GTx Inc. advanced it through Phase I and Phase II trials before development was quietly paused due to modest efficacy at doses regulators would consider safe.

The compound is still widely sold online under names like MK-2866, enobosarm, and GTx-024. Bodybuilders and physique athletes self-administer doses far above those studied in clinical trials, often 10 to 30 mg per day, a range that has never been tested in a rigorous human safety study. The FDA issued a warning in 2017 stating that SARMs are not dietary supplements and that products containing them may cause serious health risks, including the potential for heart attack and stroke [1].

How Does Ostarine Work in Muscle and Bone Tissue?

Ostarine binds the androgen receptor and causes a conformational change that recruits co-activator proteins, producing anabolic gene transcription in skeletal muscle and bone. Unlike testosterone, it does not convert to dihydrotestosterone (DHT) or estradiol at meaningful rates in most tissue compartments, which reduces, but does not eliminate, androgenic side effects.

Animal studies showed dose-dependent increases in levator ani muscle mass and bone mineral density at doses equivalent to 0.1 to 3 mg/kg/day [2]. The tissue selectivity hypothesis holds that SARMs recruit different co-regulatory proteins in muscle versus the prostate, producing anabolic effects without prostate enlargement. Human data only partially support this. The Phase II Merck trial (Study 2007-001, N=159 postmenopausal women and older men) used doses of 0.1, 0.3, 1.0, and 3.0 mg per day and found no significant prostate-specific antigen (PSA) changes, but did record measurable suppression of serum testosterone at the 3 mg dose in men [3].

What Do Clinical Trials Actually Show?

The strongest human evidence for ostarine comes from a 12-week Phase II trial published in the Journal of Cachexia, Sarcopenia and Muscle (Dalton et al., 2011, N=159). Participants receiving 3 mg per day gained a mean of 1.4 kg of lean body mass compared to placebo, while also reducing fat mass by roughly 0.6 kg. Stair-climb power improved by 15.1% versus 6.7% in the placebo group [3].

Those numbers are real. They are also modest. A 12-week resistance training program in untrained older adults typically produces 1.5 to 2.5 kg of lean mass with no drug intervention at all [4]. The GTx Phase III program (POWER trials) tested enobosarm at 3 mg per day in non-small cell lung cancer patients. Neither POWER 1 nor POWER 2 met their co-primary endpoints, a finding that contributed to the drug's development pause [5].

At bodybuilder doses of 10 to 25 mg per day, no randomized controlled trial data exist. The efficacy claims circulating on forums are anecdote, not evidence.

Testosterone Suppression and Hormonal Side Effects

Ostarine suppresses the hypothalamic-pituitary-gonadal (HPG) axis. This is dose-dependent and confirmed in clinical data. At 3 mg per day, serum total testosterone fell by approximately 43% in healthy young men in a Phase I pharmacodynamic study by Dalton et al. [6]. At bodybuilder doses, suppression is likely more severe.

Suppression begins within the first one to two weeks of use and does not always normalize quickly after cessation. Some users report post-cycle testosterone values below 200 ng/dL for four to eight weeks after stopping, meeting the clinical definition of hypogonadism during that window. Whether "post-cycle therapy" with clomiphene or tamoxifen reliably restores the HPG axis after SARM use has not been tested in any published trial.

The FDA's pharmacovigilance database includes cases of prolonged hypogonadism requiring testosterone replacement therapy after SARM use [1]. Clinicians at HealthRX see this pattern regularly in men who self-administered SARMs and then presented with fatigue, low libido, and total testosterone under 300 ng/dL.

Liver Toxicity and Safety Signals

Hepatotoxicity is the most serious safety signal associated with ostarine in real-world use. The FDA MedWatch database and published case reports document cholestatic liver injury in users who took products labeled as ostarine or MK-2866. A case series published in the Annals of Internal Medicine (Flores et al., 2020) described drug-induced liver injury (DILI) in young men using SARMs, with one case requiring hospitalization and a peak alanine aminotransferase (ALT) value exceeding 1 to 200 U/L [7].

The mechanism is not fully established. Non-steroidal SARMs lack the 17-alpha-alkylation associated with oral anabolic steroid hepatotoxicity, so the liver injury may reflect idiosyncratic immune-mediated pathways or contaminants in unregulated products. Third-party analytical testing of commercially available SARM products by the United States Anti-Doping Agency (USADA) found that up to 52% of products tested were mislabeled, meaning they contained different compounds or doses than stated on the label [8].

That contamination point matters clinically. A user who believes they are taking 10 mg of ostarine may be taking an unknown quantity of a more potent or more hepatotoxic compound.

Ostarine vs. LGD-4033 (Ligandrol)

LGD-4033 (ligandrol) is a second-generation SARM developed by Ligand Pharmaceuticals and later acquired by Viking Therapeutics. It is roughly 10-fold more potent than ostarine at the androgen receptor, meaning milligram-for-milligram it produces stronger anabolic and stronger suppressive effects.

A Phase I trial (Basaria et al., 2013, N=76 healthy young men) tested doses of 0.1, 0.3, 1.0, and 1.5 mg per day for 21 days [9]. Lean mass increased dose-dependently, and free testosterone fell dose-dependently. At 1.0 mg per day, the mean lean mass gain was 1.21 kg over just 21 days, a more pronounced short-term signal than ostarine at 3 mg per day for 12 weeks. The catch: testosterone suppression at 1.0 mg per day was severe enough that LDL-C dropped (an androgen-driven effect) and sex hormone-binding globulin fell to near-zero.

Bodybuilders typically self-administer 5 to 10 mg per day of LGD-4033, a range five to ten times higher than the highest Phase I dose. No human safety data exist for those exposures.

Ostarine vs. RAD 140 (Testolone)

RAD 140 (testolone) was developed by Radius Health for potential use in breast cancer and age-related muscle loss. Preclinical data showed near-complete selectivity for muscle and bone over the prostate in animal models, with an anabolic to androgenic ratio reported at greater than 90:1 in rat studies [10].

Human data are sparse. A Phase I trial in postmenopausal women with HR-positive breast cancer was initiated (NCT03088527), but results have not been published in full as of early 2025. Two published case reports document severe drug-induced liver injury, including one case of acute liver failure requiring liver transplant evaluation, in men who self-administered RAD 140 purchased online [11].

Compared to ostarine, RAD 140 carries a higher theoretical potency and a worse documented safety signal in the case-report literature. Using it outside a clinical trial is not supported by any human efficacy-safety balance data.

Cardarine GW501516: Not a SARM at All

Cardarine (GW501516) is frequently grouped with SARMs in bodybuilding communities, but it is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist, not an androgen receptor ligand. GlaxoSmithKline developed it as a metabolic disease treatment and halted the program in 2007 after animal studies showed rapid, dose-dependent development of cancers in multiple organ systems at doses extrapolated to human use [12].

The specific finding: in a 2-year rat carcinogenicity study, GW501516 at 5 mg/kg/day produced cancers in the colon, liver, bladder, skin, tongue, stomach, and other tissues. The World Anti-Doping Agency banned it in 2009. WADA's laboratory committee issued a specific warning in 2013 stating: "The substance has been found to cause cancer in animal studies, and use by athletes is not recommended at any dose, for any duration." [13]

No human efficacy trial for GW501516 has ever been completed. Its only appeal, modest endurance enhancement seen in rodent models, was never confirmed in a registered human trial.

Stenabolic SR9009: Oral Bioavailability Is the Problem

SR9009 (stenabolic) is a Rev-Erb agonist, a class of nuclear receptor modulators that affect circadian rhythm gene networks and mitochondrial biogenesis. Early mouse studies showed dramatic improvements in running endurance and fat oxidation at 100 mg/kg/day. Fitness forums extrapolated these results to humans as evidence of a "metabolic amplifier."

The core problem: SR9009 has approximately 2% oral bioavailability in rodents due to rapid first-pass metabolism [14]. In a species with a faster metabolic rate than humans and using intraperitoneal injection rather than oral dosing, the pharmacokinetics are entirely different. No human pharmacokinetic data have been published in a peer-reviewed journal. The dose required to achieve Rev-Erb target engagement in human tissue after oral administration is unknown.

The table below summarizes the clinical evidence tier for each compound discussed in this article. Clinicians at HealthRX use this framework when counseling patients who present with prior or intended SARM use.

| Compound | Mechanism | Highest Phase | Published Human PK/PD | Documented Human Hepatotoxicity | |---|---|---|---|---| | Ostarine (MK-2866) | SARM | Phase II | Yes | Yes (case reports) | | Ligandrol (LGD-4033) | SARM | Phase I | Yes | Yes (case reports) | | RAD 140 | SARM | Phase I (incomplete) | Limited | Yes (case reports, 1 near-transplant) | | Cardarine (GW501516) | PPAR-delta agonist | Terminated pre-Phase II | No | Insufficient data; carcinogenic in animals | | Stenabolic (SR9009) | Rev-Erb agonist | Preclinical only | No | No data |

Legal Status and Regulatory Position

Ostarine and other SARMs are not approved by the FDA for any indication. They are not legal to market or sell as dietary supplements under the Federal Food, Drug, and Cosmetic Act. In 2017, Congress passed the SARMs Control Act of 2018 (introduced to the Senate; did not pass), and in 2019 a revised version was reintroduced, seeking to add SARMs to Schedule III of the Controlled Substances Act alongside anabolic steroids. As of early 2025, that reclassification has not been enacted [1].

The current practical position: vendors sell SARMs as "research chemicals" or "not for human consumption" as a legal gray-area strategy. The FDA has pursued enforcement actions against specific companies and issued warning letters. Importing SARMs for personal use carries regulatory risk, though individual-use prosecution has been rare.

Athletes subject to anti-doping rules face a more concrete consequence. WADA's 2024 Prohibited List places all SARMs (including ostarine, LGD-4033, RAD 140, S-23, S-4, and S-22) on the S1 Anabolic Agents list, with no threshold and no therapeutic use exemption pathway [15]. Detection windows for ostarine metabolites in urine can extend to 9 days or more after a single dose.

What Physicians Should Know When Patients Present After SARM Use

Men presenting after self-administered SARM cycles require a structured workup. A baseline hormonal panel should include total testosterone, free testosterone, LH, FSH, SHBG, estradiol, and prolactin to characterize HPG axis suppression. Liver function tests (ALT, AST, ALP, GGT, total bilirubin) identify ongoing hepatotoxicity even in the absence of symptoms; cholestatic DILI from SARMs can be silent for weeks [7].

The Endocrine Society's clinical practice guideline on testosterone therapy notes that secondary hypogonadism resolves within three to six months in most cases after exogenous androgen cessation, though SARMs are not specifically addressed [16]. Recovery may take longer after high-dose or prolonged SARM exposure. Watchful waiting is appropriate for mildly suppressed patients (total testosterone 200 to 300 ng/dL) who are asymptomatic. Patients with total testosterone below 200 ng/dL and symptomatic hypogonadism four or more weeks after cessation warrant a shared decision-making conversation about short-term support, though no guideline currently provides specific SARM post-cycle recommendations.

For liver function abnormalities above three times the upper limit of normal, the provider should stop any ongoing SARM use immediately, repeat labs in two to four weeks, and consider gastroenterology referral if values do not trend downward.

Patients considering SARMs for muscle-building or body composition should be offered evidence-based alternatives. Optimizing resistance training volume, dietary protein intake (1.6 to 2.2 g per kilogram per day per the ISSN position stand) [17], and sleep quality produces lean mass changes comparable to or greater than those seen with clinical doses of ostarine, with no suppression or hepatotoxicity risk.